An evaluation of consumers’ knowledge, perceptions and attitudes regarding generic medicines in Auckland
- 692 Downloads
Objectives The aim of this project was to evaluate the perceptions, knowledge and attitudes regarding generic medicines. Methods A cross-sectional study, with self administered questionnaires, was conducted to survey consumers visiting pharmacies in four regions of Auckland (North Shore, Waitakere, Central Auckland and South Auckland). Through stratified random sampling, approximately 10% of pharmacies from each region were selected, which turn out to be 30 pharmacies. Every alternate customer coming to the pharmacy, who was eligible to participate in the study, was asked by the researchers to complete the questionnaire. Results A total of 441 questionnaires were included in the analysis. Different response rates were obtained in different regions of Auckland. Of all respondents, 51.6% had previous knowledge of generic medicines. Pharmacists were the main source of information regarding generic medicines followed by doctors and media. A higher level of education had a direct relationship with having correct knowledge of generics (P = .002). Attitude of participants toward the use of generic medicines was determined by their knowledge of generics, whether it was recommended by a pharmacist and their type of illness. Participants were more prepared to change to a generic for a minor illness (79%) than for a major illness (58.7%). Those who had better knowledge were more likely than those with poor knowledge to say they would to use a generic in major illness (P = .001) as well as minor illness (P < .0001). Previous positive experiences with generics also determined consumers’ willingness to use generics. Conclusion Many consumers have misconceptions regarding generic medicines. Having knowledge about generics and the advice by doctors and pharmacists are key indicators to improve the quality use of generic medicines.
KeywordsAttitudes Auckland Consumers Generic medicines Opinions
We would like to say thanks to Ms Rachelle Reber and the two anonymous reviewers.
The researchers’ travelling expenses were paid by the School of Pharmacy, University of Auckland.
Conflicts of interest
- 1.Glover J, Hetzel D, Tennant S. Australia and New Zealand, health systems of international encyclopedia of public health. Oxford: Academic Press; 2008. p. 255–67.Google Scholar
- 2.Organization of Economic Cooperation and Development (OECD) Health Data 2008—Version June 2008. http://www.oecd.org/dataoecd/46/36/38979632.xls. Accessed 20 Sept 2009.
- 3.PHARMAC. Pharmaceutical Management Agency Annual Review, New Zealand Government. 2007. http://www.pharmac.govt.nz/2007/11/21/ARev071.pdf. Accessed 15 Sept 2009.
- 4.Williams G, Poynton M. PHARMAC: getting the best bang for your buck since 1993—pharmacy 409 lecture. New Zealand: University of Auckland; 2009.Google Scholar
- 7.Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychol. 2001;62(5):4–9.Google Scholar
- 8.The Therapeutic Equivalence of Generic Drugs Food and Drug Administration. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm147161.htm. Accessed 15 Sept 2009.
- 9.Medsafe [Homepage on the Internet]. Information for health professionals. Interchangeable status (IMM). Wellington: New Zealand Medicines and Medical Devices Safety Authority 2006. http://www.medsafe.govt.nz/profs/imm.asp. Accessed 17 Sept 2009.
- 10.Medsafe [Homepage on the Internet]. Information for consumers. How medicines are regulated. Wellington: New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz/consumers/regulate.asp. Accessed 16 Sept 2009.
- 11.Medsafe. New Zealand regulatory guidelines for medicines. vol 1, 6.3 ed. Wellington: Medsafe. 2009. http://medsafe.govt.nz/regulatory/Guideline/Full%20-%20NZ%20Regulatory%20Guidelines%20for%20Medicines.pdf. Accessed 19 Sept 2009.
- 14.Minutes of the PHARMAC Consumer Advisory Committee (CAC) Meeting, Friday 13 July 2007. Wellington, New Zealand: PHARMAC. http://www.pharmac.govt.nz/pdf/021007a.pdf. Accessed 18 Sept 2009.
- 15.Generic Medicines: Dealing with Mutliple Brands. National Prescribing Service Newsletter. NPS News 55. 2007. http://www.nps.org.au/__data/assets/pdf_file/0008/23867/news55.pdf. Accessed 15 Sept 2009.
- 17.Ministry of Health. Primary health care: pharmaceutical co-payments. 2007. http://www.moh.govt.nz/moh.nsf/indexmh/phcs-funding-pharmaceutical. Accessed 17 Sept 2009.
- 18.Medsafe [Homepage on the Internet]. Information for health professionals. Regulatory issues. No immediate change to generic. Wellington: New Zealand Medicines and Medical Devices Safety Authority. http://www.medsafe.govt.nz/profs/riss/gensubleg.asp#No. Accessed 17 Sept 2009.
- 19.Upfront: Brand Change. Changing to a generic drug. BPac NZ. 2007. http://www.bpac.org.nz/magazine/2007/june/upfront.asp. Accessed 1 May 2008.
- 20.Al-Gedadi NA, Hassali MA, Shafie AA. A pilot survey on perceptions and knowledge of generic medicines among consumers in Penang, Malaysia. Pharm Pract. 2008;6(2):93–7.Google Scholar
- 22.Ministry of Health. Towards a New Zealand medicines strategy consultation document. 2006. http://www.moh.govt.nz/moh.nsf/pagesmh/5633. Accessed 14 June 2010
- 23.Statistics New Zealand. Demographic trends: 2007. Wellington: Statistics New Zealand. 2008. http://search.stats.govt.nz/search?p=Q&ts=custom&w=demographics. Accessed 14 June 2010
- 24.Latin American conference on economic aspects of essential medicines. World Health Organisation; 1992.Google Scholar
- 28.Gaither CA, Kirking DM, Ascione FJ, Welage LS. Consumers’ views on generic medications. J Am Pharm Assoc. 2001;41(5):729–36.Google Scholar
- 35.Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc (Wash). 2000;40(3):378–83.Google Scholar